Grow Your Retirement Account With This Trade!
Whether you’re close to retirement or have barely begun your career, "How To Master the Retirement Trade" by expert Dave Aquino is the guide you’ve been waiting for.

Take advantage of a little known trade window and watch retirement come sooner than you ever thought possible.
Get your copy now!
Samantha Prout Insider Alerts

Get notified the next time Samantha Prout buys or sells Amicus Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Samantha Prout Insider Information



Samantha Whiteman Prout CPA serves as Principal Accounting Officer, Vice President - Finance, Controller of the Company. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy (“NRG”), first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in New Jersey. Ms. Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant in New Jersey.

What is Samantha Prout's net worth?

The estimated net worth of Samantha Prout is at least $784,231.50 as of September 3rd, 2021. Ms. Prout owns 85,150 shares of Amicus Therapeutics stock worth more than $784,232 as of January 20th. This net worth estimate does not reflect any other investments that Ms. Prout may own. Learn More.

How do I contact Samantha Prout?

The corporate mailing address for Ms. Prout and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]

Has Samantha Prout been buying or selling shares of Amicus Therapeutics?

Samantha Prout has not been actively trading shares of Amicus Therapeutics during the last quarter. Most recently, Samantha Prout sold 4,925 shares of the business's stock in a transaction on Friday, September 3rd. The shares were sold at an average price of $12.01, for a transaction totalling $59,149.25. Following the completion of the sale, the insider now directly owns 85,150 shares of the company's stock, valued at $1,022,651.50.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (COO), Bradley Campbell (COO), John Crowley (CEO), John Crowley (CEO), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director).

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 8 times. They purchased a total of 39,105 shares worth more than $354,377.70. During the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 569,658 shares worth more than $6,693,258.28. The most recent insider tranaction occured on January, 18th when CEO John F Crowley sold 8,564 shares worth more than $87,609.72. Insiders at Amicus Therapeutics own 2.5 % of the company.

Information on this page was last updated on 1/18/2022.

Samantha Prout Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/3/2021Sell4,925$12.01$59,149.2585,150View SEC Filing Icon  
8/23/2021Sell5,045$11.00$55,495.0083,170View SEC Filing Icon  
11/4/2020Sell5,931$20.00$118,620.0022,472View SEC Filing Icon  
8/5/2020Sell198$15.05$2,979.9017,333View SEC Filing Icon  
7/2/2020Sell198$15.80$3,128.401,733View SEC Filing Icon  
6/19/2020Sell3,366$15.00$50,490.0020,501View SEC Filing Icon  
See Full Table

Samantha Prout Buying and Selling Activity at Amicus Therapeutics

This chart shows Samantha Prout's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.
Read More

Today's Range

Now: $9.21
Low: $9.18
High: $9.91

50 Day Range

MA: $11.04
Low: $9.21
High: $12.48

2 Week Range

Now: $9.21
Low: $8.40
High: $21.34

Volume

2,238,868 shs

Average Volume

4,022,053 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21
1,000X Bigger than Crypto? ($25 Gets You In) 
LIVE ON CAMERA: The man who called #1 tech stocks of 2016, 2018, 2019 & 2020 based on return…

Reveals the details of a new tech set to grow: 113X bigger than the Internet… 600X bigger than 5G… 2,000X BIGGER than Bitcoin… "This is the biggest investing moment in 400 years — and just $25 gets you in."

Brown believes the rollout could be days away...
Watch Jeff's presentation HERE before it's too late.